Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 62 VictozaⓇ statistically significantly reduced the risk of major adverse cardiovascular events in the LEADER trial 13% reduction in 3-point MACE with Victoza® compared with placebo Patients¹ with an event (%) 20 15 10 5 Hazard ratio = 0.87 VictozaⓇ 95% CI (0.78;0.97) p<0.001 for non-inferiority p=0.011 for superiority Placebo Key results • Superiority of VictozaⓇ vs placebo was confirmed for time to • first MACE in people with type 2 diabetes at high CV risk VictozaⓇ reduced the MACE risk by 13% as well as CV and all-cause mortality by 22% and 15% respectively, compared with placebo when added to standard of care • The result was consistent across sensitivity analyses • VictozaⓇ appeared to have a safe and well tolerated profile, generally consistent with previous studies for VictozaⓇ 0 18 24 30 36 42 48 54 0 6 12 Time from randomisation (months) ¹Inclusion criteria: Adults above 50 years with type 2 diabetes and established CV disease, above 60 years with multiple CV factors, HbA1c ≥ 7.0% MACE: major adverse cardiovascular events; 3-point MACE comprises cardiovascular death, non-fatal myocardial infarction and non-fatal stroke; CI: two-sided confidence interval changing diabetes® CV: Cardiovascular novo nordisk

View entire presentation